Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue
- 173 Downloads
Levocarnitine is an important contributor to cellular energy metabolism. This study aims to evaluate the effects of levocarnitine supplementation on body composition, lipid profile and fatigue in elderly subjects with rapid muscle fatigue.
This was a placebo-controlled, randomised, double-blind, two-phase study. Eighty-four elderly subjects with onset of fatigue following slight physical activity were recruited to the study. Prior to randomisation all patients entered a 2-week normalisation phase where they were given an ‘ad libitum’ diet, according to the National Cholesterol Education Program (Step 2). Subjects were asked to record their daily food intake every 2 days. Before the 30-day treatment phase, subjects were randomly assigned to two groups (matched for male/female ratio, age and body mass index). One group received levocarnitine 2g twice daily (n = 42) and the other placebo (n = 42). Efficacy measures included changes in total fat mass, total muscle mass, serum triglyceride, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), apolipoprotein (apo)A1, and apoB levels. The Wessely and Powell scale was used to evaluate physical and mental fatigue. Subjects were assessed at the beginning and end of the study period.
At the end of the study, compared with placebo, the levocarnitine-treated patients showed significant improvements in the following parameters: total fat mass (−3.1 vs −0.5 kg), total muscle mass (+2.1 vs +0.2 kg), total cholesterol (−1.2 vs +0.1 mmol/L), LDL-C (−1.1 vs −0.2 mmol/L), HDL-C (+0.2 vs +0.01 mmol/ L), triglycerides (−0.3 vs 0.0 mmol/L), apoA1 (−0.2 vs 0.0 g/L), and apoB (−0.3 vs −0.1 g/L). Wessely and Powell scores decreased significantly by 40% (physical fatigue) and 45% (mental fatigue) in subjects taking levocarnitine, compared with 11% and 8%, respectively, in the placebo group (p < 0.001 vs placebo for both parameters). No adverse events were reported in any treatment group.
Administration of levocarnitine to healthy elderly subjects resulted in a reduction of total fat mass, an increase of total muscle mass, and appeared to exert a favourable effect on fatigue and serum lipids.
KeywordsCarnitine Elderly Subject Chronic Fatigue Syndrome Mental Fatigue Serum Lipid Profile
The authors thank Steven Dawber for his expert editorial assistance. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
- 1.Larsoon L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–6Google Scholar
- 8.Brenner J. Carnitine metabolism and functions. Physiol Rev 1983; 63: 1420–80Google Scholar
- 16.Lipid Research Clinics. Population studies data book. Vol. 2. The prevalence study: nutrient intake. Washington, DC. Govt Printing Office, 1982Google Scholar
- 17.Centers for Disease Control and Prevention. Prevalence of health care providers asking older adults about their physical activity levels: USA 1998. MMWR Morb Mortal Wkly Rep 2002; 51: 412–4Google Scholar